Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Update

Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 2,400 shares, a growth of 84.6% from the March 31st total of 1,300 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 19,700 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Trading of Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. Allianz SE acquired a new position in Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 103,250 shares of the company's stock, valued at approximately $444,000. Allianz SE owned approximately 0.56% of Genenta Science at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.13% of the company's stock.

Genenta Science Stock Performance

GNTA stock remained flat at $3.97 during trading on Friday. The company's stock had a trading volume of 1 shares, compared to its average volume of 14,885. The firm's 50 day moving average is $3.87 and its 200 day moving average is $4.42. Genenta Science has a 52 week low of $2.79 and a 52 week high of $7.28.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.